245 related articles for article (PubMed ID: 19075049)
1. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
Arroyo LA; Mateos I; González V; Aznar J
Antimicrob Agents Chemother; 2009 Mar; 53(3):1295-6. PubMed ID: 19075049
[No Abstract] [Full Text] [Related]
2. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
[TBL] [Abstract][Full Text] [Related]
3. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii.
Ozbek B; Sentürk A
Chemotherapy; 2010; 56(6):466-71. PubMed ID: 21088399
[TBL] [Abstract][Full Text] [Related]
4. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates.
Ricciardi R; Ricciardi AM; Danzi G
Infez Med; 2009 Dec; 17(4):236-9. PubMed ID: 20046104
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
[TBL] [Abstract][Full Text] [Related]
8. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
[TBL] [Abstract][Full Text] [Related]
9. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals.
Al-Sweih NA; Al-Hubail MA; Rotimi VO
J Chemother; 2011 Feb; 23(1):13-6. PubMed ID: 21482488
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
Ozbek B; Otük G
Int J Antimicrob Agents; 2010 Aug; 36(2):191-2. PubMed ID: 20537868
[No Abstract] [Full Text] [Related]
11. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.
Principe L; D'Arezzo S; Capone A; Petrosillo N; Visca P
Ann Clin Microbiol Antimicrob; 2009 May; 8():18. PubMed ID: 19460166
[TBL] [Abstract][Full Text] [Related]
12. Rapid spread of multiresistant Acinetobacter baumannii isolates in intensive care units (ICUs) and in vitro activity of colistin and tigecycline.
Buccoliero G; Morelli E; Lonero G; Romanelli C; Resta F; Pisconti S
Infez Med; 2012 Dec; 20(4):296-8. PubMed ID: 23299072
[No Abstract] [Full Text] [Related]
13. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period.
Spiliopoulou A; Jelastopulu E; Vamvakopoulou S; Bartzavali C; Kolonitsiou F; Anastassiou ED; Christofidou M
J Chemother; 2015 Oct; 27(5):266-70. PubMed ID: 24827985
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
Piewngam P; Kiratisin P
Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358
[TBL] [Abstract][Full Text] [Related]
15. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects.
Candel FJ; Calvo N; Head J; Sánchez A; Matesanz M; Culebras E; Barrientos A; Picazo J
Rev Esp Quimioter; 2010 Jun; 23(2):103-8. PubMed ID: 20559610
[TBL] [Abstract][Full Text] [Related]
16. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
[TBL] [Abstract][Full Text] [Related]
18. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants.
Bahador A; Taheri M; Pourakbari B; Hashemizadeh Z; Rostami H; Mansoori N; Raoofian R
Microb Drug Resist; 2013 Oct; 19(5):397-406. PubMed ID: 23768166
[TBL] [Abstract][Full Text] [Related]
19. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
Cakirlar FK; Ciftci IH; Gonullu N
Clin Lab; 2015; 61(7):741-7. PubMed ID: 26299073
[TBL] [Abstract][Full Text] [Related]
20. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.
Cui JC; Liu YN; Chen LA
J Antibiot (Tokyo); 2010 Jan; 63(1):29-31. PubMed ID: 19911030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
